Jinfeng Biotechnology Completes a $10 Million Pre-A Round of Financing

Jinfeng Biotechnology recently completed a $10 million Pre-A round of financing, led by Hanne Capital and VI Ventures. This round of financing funds will be mainly used for the upgrade of the Jinfeng Biotechnology platform, the construction of the patent pool and the construction of related teams.

Jinfeng Bio was formally established this year and is a rising star in the field of tumor treatment. The company was founded by Dr. Fuli Yu, who has rich experience in medical technology product research and development and corporate management, focusing on the rapid advancement of tumor cell therapy product research and development and clinical applications.

As a biotechnology company, Jinfeng Biotechnology breaks through the bottleneck of tumor liquid biopsy and single-cell sequencing technology based on genomics and proteomics. It combines non-invasive tumor detection and screening in the field of precision cell therapy research and development and application, and uses biological Information technology and artificial intelligence technology deeply excavate tumor multi-omics data, in order to intelligently optimize cell therapy strategies, improve the effectiveness of tumor treatment, and improve the quality of life of patients.

It is reported that Jinfeng Bio has been recognized by well-known experts in the industry before its establishment. Professor Brendan Lee, a member of the American Academy of Sciences and the head of the Department of Genetics of Baylor College of Medicine, based on the achievements of Dr. Welfare in scientific research and industry, and his Independently judge the overall development of the industry, he became an angel investor in Jinfeng Biologics at the beginning of its planning, and currently he is also an SAB expert.

Founded in 2017, Hanne Capital is a healthcare venture capital fund focusing on growth opportunities in the Greater China. The Founding Partners are industry veterans with years of senior leadership experience in leading private equity fund or world-renowned multinationals in biotech, pharma and medtech; and have accomplished significant industry milestones in their previous careers. The Hanne team consists of seasoned professionals with sharp business acumen, rich experience of investment and entrepreneurial background.

VI Ventures provides venture capital investment services. The Company invests in technology, media, telecom, and medical technology companies in China, U.S. and Israel. VI Ventures also provides branding, marketing, channel development, overseas expansion, human resources, and finance services.